文献速递炎症性肠病

维多珠单抗与肿瘤坏死因子拮抗剂治疗溃疡性结肠炎的安全性和有效性比较

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-08

多中心回顾性观察性队列研究(2014年5月至2017年12月)纳入722例溃疡性结肠炎患者(维多珠单抗454例,TNF拮抗剂268例),倾向评分加权比较显示维多珠单抗组临床缓解、无激素临床缓解和无激素深度缓解率均高于TNF拮抗剂组,总体严重不良事件和严重感染风险无统计学显著差异,但在未使用过TNF拮抗剂的患者中维多珠单抗组严重不良事件风险更低。

要点

  • 维多珠单抗组临床缓解率高于TNF拮抗剂组(HR 1.651,95%CI 1.229-2.217)。
  • 总体严重不良事件(HR 0.899,95%CI 0.502-1.612)和严重感染(HR 1.235,95%CI 0.608-2.511)风险无统计学显著差异。
  • 未使用过TNF拮抗剂患者中,维多珠单抗组严重不良事件风险低于TNF拮抗剂组(HR 0.192,95%CI 0.049-0.754)。

核心结论

  • 在常规实践中,维多珠单抗治疗溃疡性结肠炎的缓解率高于TNF拮抗剂治疗,且在未使用过TNF拮抗剂的患者中严重不良事件发生率更低。

研究设计与样本

  • 多中心、回顾性、观察性队列研究,纳入2014年5月至2017年12月接受维多珠单抗或TNF拮抗剂治疗的溃疡性结肠炎患者,共722例(维多珠单抗454例,TNF拮抗剂268例),采用倾向评分加权比较。

主要发现

  • 维多珠单抗组较TNF拮抗剂组更可能达到临床缓解(HR 1.651;95%CI 1.229-2.217)。
  • 维多珠单抗组较TNF拮抗剂组更可能达到无激素临床缓解(HR 1.828;95%CI 1.135-2.944)。
  • 维多珠单抗组较TNF拮抗剂组更可能达到无激素深度缓解(HR 2.819;95%CI 1.496-5.310)。
  • 总体严重不良事件风险(HR 0.899;95%CI 0.502-1.612)和严重感染风险(HR 1.235;95%CI 0.608-2.511)在两组间无统计学显著差异。
  • 在未使用过TNF拮抗剂的患者中,维多珠单抗组严重不良事件风险低于TNF拮抗剂组(HR 0.192;95%CI 0.049-0.754)。

关键数值与推荐

  • 亚组分析(未使用过TNF拮抗剂和已使用过TNF拮抗剂患者,以及维多珠单抗分别对比英夫利西单抗和皮下TNF拮抗剂)结果与总体一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. METHODS: A multicenter, retrospective, observational cohort study (May 2014 to December 2017) of ulcerative colitis patients treated with vedolizumab or TNF-antagonist therapy. Propensity score weighted comparisons for development of serious adverse events and achievement of clinical remission, steroid-free clinical remission, and steroid-free deep remission. A priori determined subgroup comparisons in TNF-antagonist-naïve and -exposed patients, and for vedolizumab against infliximab and subcutaneous TNF-antagonists separately. RESULTS: A total of 722 (454 vedolizumab, 268 TNF antagonist) patients were included. Vedolizumab-treated patients were more likely to achieve clinical remission (hazard ratio [HR], 1.651; 95% confidence interval [CI], 1.229-2.217), steroid-free clinical remission (HR, 1.828; 95% CI, 1.135-2.944), and steroid-free deep remission (HR, 2.819; 95% CI, 1.496-5.310) than those treated with TNF antagonists. Results were consistent across subgroup analyses in TNF-antagonist-naïve and -exposed patients, and for vedolizumab vs infliximab and vs subcutaneous TNF-antagonist agents separately. Overall, there were no statistically significant differences in the risk of serious adverse events (HR, 0.899; 95% CI, 0.502-1.612) or serious infections (HR, 1.235; 95% CI, 0.608-2.511) between vedolizumab-treated and TNF-antagonist-treated patients. However, in TNF-antagonist-naïve patients, vedolizumab was less likely to be associated with serious adverse events than TNF antagonists (HR, 0.192; 95% CI, 0.049-0.754). CONCLUSIONS: Treatment of ulcerative colitis with vedolizumab is associated with higher rates of remission than treatment with TNF-antagonist therapy in routine practice, and lower rates of serious adverse events in TNF-antagonist-naïve patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lukin D, Faleck D, Xu R, et al. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 33039584. doi:10.1016/j.cgh.2020.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。